Additional file 1 of Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
Creators: name: Gao, Xiaoqiang
name: Zhao, Rui
name: Ma, Huaxing
name: Zuo, Shi
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Pharmacology
subject: Biotechnology
subject: Environmental Sciences not elsewhere classified
subject: Chemical Sciences not elsewhere classified
subject: Ecology
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Science Policy
subject: Plant Biology

description: Additional file 1: Supplementary Fig. 1. Pooled OR rates of first-line and second- or later-line treatment with atezolizumab plus bevacizumab. (A) Pooled OR rate of first-line treatment based on RECIST. (B) Pooled OR rate of first-line treatment based on mRECIST. (C) Pooled OR rate of second- or later-line treatment based on RECIST. (D) Pooled OR rate of second- or later-line based on mRECIST. OR, overall response; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST. Supplementary Fig. 2. Pooled CR rates of first-line and second- or later-line treatment with atezolizumab plus bevacizumab. (A) Pooled CR rate of first-line treatment based on RECIST. (B) Pooled CR rate of first-line treatment based on mRECIST. (C) Pooled CR rate of second- or later-line treatment based on RECIST. (D) Pooled CR rate of second- or later-line based on mRECIST. CR, complete response; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST. Supplementary Fig. 3. Pooled PR rates of first-line and second- or later-line treatment with atezolizumab plus bevacizumab. (A) Pooled PR rate of first-line treatment based on RECIST. (B) Pooled PR rate of first-line treatment based on mRECIST. (C) Pooled PR rate of second- or later-line treatment based on RECIST. (D) Pooled PR rate of second- or later-line based on mRECIST. PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST. Supplementary Fig. 4. Pooled OR rates based on different inclusion criteria and different doses of atezolizumab plus bevacizumab. (A) Pooled OR rate of the IMbrave-IN group based on RECIST. (B) Pooled OR rate of IMbrave-OUT group based on RECIST. (C) Pooled OR rate of standard dose (1200 mg of atezolizumab plus 15 mg/kg of bevacizumab) therapy based on RECIST. (D) Pooled OR rate of low dose (1200 mg of atezolizumab plus 5–7.5 mg/kg of bevacizumab) therapy based on RECIST. OR, overall response; RECIST, Response Evaluation Criteria in Solid Tumors. Supplementary Fig. 5. The results of sensitivity analysis. (A) OR rate of non-early treatment based on RECIST. (B) OR rate of non-early treatment based on mRECIST. (C) OR rate of early treatment based on RECIST. (D) OR rate of early treatment based on mRECIST. (E) CR rate of early treatment based on mRECIST. (F) CR rate of non-early treatment based on RECIST. (G) CR rate of non-early treatment based on mRECIST. (H) PR rate of early treatment based on RECIST. (I) PR rate of early treatment based on mRECIST. (J) PR rate of non-early treatment based on RECIST. (K) PR rate of non-early treatment based on mRECIST. (L) Incidence of all-grade AEs. (M) Incidence of grade 3 and above AEs. (N) median overall survival. (O) median progression-free survival. OR, overall response; CR, complete response; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST. AEs, adverse events.